Canine Myasthenia Gravis: Welfare Management

Myasthenia gravis is an immune-mediated neuromuscular disease in dogs causing progressive weakness and life-threatening aspiration pneumonia.

Key Facts

Myasthenia gravis results from autoantibodies targeting acetylcholine receptors at the neuromuscular junction
Acquired MG is most common in middle-aged large breed dogs and certain terrier breeds
Regurgitation from megaesophagus occurs in over 80% of cases and is the primary cause of death
Aspiration pneumonia kills approximately 50% of affected dogs if megaesophagus is not managed
Some dogs achieve spontaneous remission within 6-18 months with appropriate treatment

Welfare Considerations

Dogs with MG suffer progressive exercise intolerance, weakness, and the distressing experience of regurgitating food and water due to megaesophagus. Recurrent aspiration pneumonia causes severe respiratory distress. Managing megaesophagus requires upright feeding using special chairs that hold dogs vertical for 15-20 minutes after meals. This intensive management is burdensome for owners but substantially reduces aspiration risk and improves welfare. Prognosis depends heavily on the presence and severity of aspiration pneumonia and early initiation of appropriate treatment.

What You Can Do

Learn to recognize early signs of MG including exercise intolerance and regurgitation
Support specialist veterinary referral for confirmed or suspected MG cases
Connect with online communities supporting owners of dogs with megaesophagus for management advice
Ask your vet about regular monitoring during treatment to detect remission or relapse